Abstract
Advanced melanoma is a highly aggressive tumour where it is not possible to rule out subsequent spread and formation of distant metastases even after its radical removal. One way how to prevent disease relapse is adjuvant therapy.
New therapeutic procedures, immunotherapy with monoclonal antibodies targeting inhibitory receptors on T cells - CTLA-4 (cytotoxic T-lymphocyte antigen 4) and PD-1 (programmed death 1) - and targeted therapy with BRAF and MEK inhibitors that have shown clear efficacy in the therapy of metastatic melanoma, are effective also as adjuvant therapy. Adjuvant immunotherapy and targeted therapy extend the time to disease relapse, delay the development of distant metastases, and extend overall patient survival following surgery of advanced melanomas